Thanks to a sound financial situation, the firm has significant leeway for investment.
The stock, which is currently worth 2024 to 0.01 times its sales, is clearly overvalued in comparison with peers.
The company's share price in relation to its net book value makes it look relatively cheap.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.